BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies.Clinical Trial number: NCT05471856.
Journal article
2025-01-01T00:00:00+00:00
21
195 - 200
5
The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, London, UK.
Humans, Neoplasms, Membrane Proteins, Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Maximum Tolerated Dose, Adult, Aged, Middle Aged, Female, Male, Clinical Trials, Phase I as Topic, STING Protein